The CEO's option exercise and sale is a standard cashless exercise pattern — not a bearish signal. The EVP's sale is also routine for a $10B+ biotech. Monitor next earnings for aflatamet (CK-586) pipeline updates, but this insider activity provides no actionable trading signal.
Price Chart
Executive Summary
Cytokinetics CEO Robert Blum exercised and sold 7,490 shares for ~$614K on July 13, and EVP R&D Fady Malik sold 3,500 shares for ~$303K on July 7. The CEO's sale follows a derivative exercise at $10.60, representing a large realized gain. The total cluster value of ~$917K is ~0.009% of the $10.2B market cap — trivial relative to company size. These are routine liquidity-driven sales, not a bearish signal.
Key Financial Metrics
Key Facts
- CEO Blum exercised 7,490 options at $10.60/share and immediately sold the shares at $82.02, netting ~$614K in proceeds
- EVP R&D Malik sold 3,500 shares at $86.62 for ~$303K on July 7
- Total cluster value of ~$917K represents ~0.009% of CYTK's $10.2B market cap
- Both sales are open-market transactions; no 10b5-1 plan indicated
- Cytokinetics has strong analyst consensus (89% bullish) with 25 buy-equivalent ratings
Financial Impact
Total insider sales of ~$917K, less than 0.01% of market cap — immaterial
Risk Factors
- Insider sales could increase if additional option exercises occur near expiration
- No 10b5-1 plan disclosed — future sales may be unpredictable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1784057701171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access